This meta-analysis aimed to evaluate the specific effect of adjunctive SGLT2i therapy on fracture risk in patients with type 1 diabetes mellitus (T1DM).<h4>Methods</h4>We systematically searched four databases (PubMed, Embase, Cochrane Library and Web of Science Core Collection) to identifyall eligible randomized controlled trials (RCTs) investigating SGLT2i as adjunctive therapy to insulin in T1DM. The gene discussed is INS; the disease is type 1 diabetes mellitus.